Hope for rare liver disease: new drug trial aims to slow damage
NCT ID NCT07387549
First seen Feb 04, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tests a drug called elafibranor in 350 adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts and can lead to liver failure. Participants will take either elafibranor or a placebo daily for several years to see if the drug delays disease progression or death. The goal is to control the disease and improve survival, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at The Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.